Cristian D. Mendieta-Barrera

Cristian D. Mendieta-Barrera

Auto-generated profile, based on publicly available information

Cristian D. Mendieta-Barrera

Universidad Mayor Real y Pontificia de San Francisco Xavier, Chuquisaca, Bolivia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2024 in World Neurosurgery
Verified
Journal Article
Closed access
JBJhon E. Bocanegra-Becerra
Jhon E. Bocanegra-Becerra
JSJosé Luis Acha Sánchez
José Luis Acha Sánchez
ACAdriam M. Castilla-Encinas
Adriam M. Castilla-Encinas
WRWagner Rios-Garcia
Wagner Rios-Garcia
CMCristian D. Mendieta
Cristian D. Mendieta
MGMIGUEL ANGEL LOPEZ GONZALEZ
MIGUEL ANGEL LOPEZ GONZALEZ


9 May 2025 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Open access
CMCristian D. Mendieta-Barrera
Cristian D. Mendieta-Barrera
APAnuraag Punukollu
Anuraag Punukollu
CRCamila Rios-Hurtado
Camila Rios-Hurtado
FVFernando De Nigris Vasconcellos
Fernando De Nigris Vasconcellos
FGFabricio Garcia-Torrico
Fabricio Garcia-Torrico
AGArash Ghaffari-Rafi
Arash Ghaffari-Rafi
Neurocysticercosis is parasitic infection responsible for intraventricular cysts and consequent obstructive hydrocephalus. While the cysts are sometimes treated endoscopically, the efficacy and safety of neuroendoscopic management for intraventricular neurocysticercosis (IVNCC) remains unclear. Therefore, we conducted a systematic review and meta-analysis to evaluate management outcomes of endoscopic IVNCC. Following PRISMA guidelines, a search of MEDLINE, Embase, and Lilacs databases was performed (inception to September 10, 2024), focusing on the neuroendoscopic management of IVNCC. Eligible studies included at least five patients and reported outcomes of cyst resection and complication rates. Fifteen studies met our inclusion criteria (n = 314 patients). Mean age at diagnosis was 20.6 years, with 55.6 % (n = 138) patients male, and 44 % (n = 138) of cysts in the fourth ventricle, 32.8 % (n = 104) in the third, and 28.7 % in the lateral ventricles. Preoperative hydrocephalus was observed in 92.3 % (n = 203) of cases. Complete cyst resection was achieved in 90.1 % (n = 214) of patients, with the highest success rates noted in third ventricular cysts (99.6 %; compared to 89.0 % in the lateral and 85.0 % in the fourth ventricles). Flexible endoscopy demonstrated superior outcomes for fourth ventricle cysts (100 %) relative to the rigid endoscope (79.0 %, p < 0.01). Non-visualization of cysts was the primary etiology for incomplete resection (1.6 %). Intraoperative complications included bleeding at 0.76 % (n = 6) and cyst rupture at 0.48 % (n = 5). Postoperative complications involved seizures (1.6 %), neurological deficits (0.95 %), and infection-related mortality (0.85 %). The reintervention rate was 3.0 % (n = 18), with the intervention primarily being cranial shunt implantation. Postoperative anthelmintic therapy significantly improved outcomes from 69.0 % to 96.0 % (p < 0.01). Neuroendoscopic management of IVNCC is effective and safe. Higher resection rates are achieved with the flexible endoscope, likely secondary to enhanced visualization. Finally, adjuvant postoperative anthelmintic therapy significantly improved outcomes.

3 April 2025 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
CMCristian D. Mendieta-Barrera
Cristian D. Mendieta-Barrera
FVFernando De Nigris Vasconcellos
Fernando De Nigris Vasconcellos
KMKevin Mamani-Julian
Kevin Mamani-Julian
PFPriscilla Isabel Freeman
Priscilla Isabel Freeman
FGFabricio Garcia-Torrico
Fabricio Garcia-Torrico
EBEmanuela Binello
Emanuela Binello

6 March 2026 in Acta Neurochirurgica
Verified
Journal Article
Open access
PDF file
CMCristian D. Mendieta-Barrera
Cristian D. Mendieta-Barrera
PDPavell Dhondt
Pavell Dhondt
APAnuraag Punukollu
Anuraag Punukollu
FGFabricio Garcia-Torrico
Fabricio Garcia-Torrico
DODiana Laura Ochoa-Hernández
Diana Laura Ochoa-Hernández
AGArash Ghaffari-Rafi
Arash Ghaffari-Rafi
Background/objectives: Despite space-occupying cerebellar infarctions (SOCIs) carrying a high morbidity and mortality due to mass effect in the posterior fossa, optimal management remains uncertain: particularly regarding patient selection, timing, and surgical technique. We conducted a systematic review and network meta-analysis to compare outcomes between medical versus surgical management, and to identify prognostic thresholds that may guide treatment. Methods: A search of PubMed, Embase, and CENTRAL was performed from database inception through October 30, 2024. Studies were included if they reported outcomes in ≥ 10 patients with SOCI treated with medical management and/or surgical interventions, including suboccipital decompressive craniectomy (SDC), external ventricular drainage (EVD), and necrosectomy. Data extraction and risk-of-bias assessment were performed independently by multiple reviewers. Random-effects meta-analyses and frequentist network meta-analyses were conducted. Primary outcomes were favorable functional status and mortality; secondary outcomes included length of hospital stay. Results: Eighteen studies comprising 754 patients met inclusion criteria. Surgical intervention was associated with superior outcomes in patients with infarct volumes > 51 mL (61.5% favorable outcome vs. 35.0% with medical therapy; p = 0.018) or GCS ≤ 13 ( p < 0.05). Among surgical strategies, SDC combined with necrosectomy and an EVD (SDC–N–EVD) conferred the greatest probability of favorable outcome (OR 3.1, 95% CI: 1.18–8.14; p < 0.05), reduced mortality risk, and shortened length of hospitalization. Neither patient age nor surgical timing within 72 h significantly altered outcomes. Conclusions: Surgical management, particularly SDC–N–EVD, was associated with improved outcomes compared to medical therapy alone for SOCI, especially in patients with large infarcts or impaired consciousness. Infarct volume and pre-interventional GCS can provide prognostic thresholds. While the inherent heterogeneity of the data indicates these results should be interpreted with caution, they provide impetus for conducting standardized multicenter prospective studies to validate these observations and establish evidence-based treatment algorithms.

27 September 2024 in Research Square
Verified
Preprint
Open access
PDF file
CMCristian Mendieta
Cristian Mendieta
MSMarina Barbosa Da Silva
Marina Barbosa Da Silva
LNLivia Aguiar Nogueira-Rosa
Livia Aguiar Nogueira-Rosa
DFDomênica Baroni Coelho de Oliveira Ferreira
Domênica Baroni Coelho de Oliveira Ferreira
JBJhon Bocanegra-Becerra
Jhon Bocanegra-Becerra
NFNathalia Moraes Figueiredo
Nathalia Moraes Figueiredo
Oxcarbazepine (OXC) has demonstrated comparable efficacy to Carbamazepine (CBZ) in the treatment of Trigeminal neuralgia (TN), with the added benefit of fewer adverse events (AEs). Whether it can be used as a substitute for carbamazepine is yet to be verified. To address this, we conducted a comprehensive meta-analysis, exploring efficacy and adverse events in detail. We searched PubMed, Embase, Cochrane Library, and Google Scholar for studies comparing CBZ to OXC in patients with TN. The main outcomes were efficacy, AEs, frequency of neurological AEs, skin reactions, and alterations in laboratory parameters. Statistical analysis was performed using Review Manager 5.4.1. And the risk of bias was assessed using RoB-2 and ROBINS-I. We included 838 patients from three observational studies and two randomized clinical trials (RCTs). CBZ was used to treat TN in 445 (53.1%) patients. The CBZ group when compared with the OXC group had no significant difference in efficacy (OR:0.58; 95% Cl:0.14-2.40; p=0.45). Both groups had significant differences noted in AEs, with higher frequency observed in the CBZ group (OR:2.30; 95% Cl:1.49-3.54; p=0.0002). Similarly, there was a significant difference in neurological AEs (OR:2.76; 95% Cl:1.53-4.87; p=0.0007). OXC and CBZ demonstrated similar efficacy in treating trigeminal neuralgia. However, the consideration of adverse events may favor clinical decision-making to OXC due to its superiority. Nonetheless, more randomized controlled trials (RCTs) are necessary to confirm this conclusion in the future